丽珠医药(01513)子公司四川光大获批开展天葛定眩颗粒前庭性偏头痛临床试验

公告速递
Oct 27

丽珠医药(01513)10月27日公告称,其子公司四川光大制药有限公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》(通知书编号:2026LP03296),同意其申报的中药1.1类创新药天葛定眩颗粒在“前庭性偏头痛(风痰挟瘀、上扰清窍证)”适应症开展临床试验。\n\n该品种剂型为颗粒剂,规格为每袋装7g(每1g相当于饮片2.97g)。本次临床试验申请于2026年8月17日获得受理,经审评后获批需在进一步完善临床试验方案的基础上实施。\n\n天葛定眩颗粒以天麻、葛根等为主要成分,拟用于治疗前庭性偏头痛。公开资料显示,目前全球及中国均无药物获批该适应症,临床治疗多参照偏头痛用药,存在未被满足的临床需求。\n\n非临床研究方面,药效学试验证实该品种可改善偏头痛模型动物的痛觉敏感及平衡、运动协调障碍,并降低血浆一氧化氮、降钙素基因相关肽水平;毒理学研究显示,大鼠单次给药最大耐受量相当于预防期临床日剂量的293~327倍,13周重复给药未见明显毒性反应的剂量为临床拟用量的14.1倍。\n\n截至公告披露日,天葛定眩颗粒累计直接投入研发费用约733.58万元。丽珠医药与北京中医药大学东方医院合作研发该产品,并在全球范围内享有全部权益。\n\n公司提示,药物须在完成临床试验并通过国家药监局审评、审批后方可生产上市,研发及市场化进程存在不确定性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10